NCT07171554

Evaluation of a Diagnostic Test to Identify the Best Drugs for Treatment of Metastatic Colorectal Cancer

Clinical Performance Study of a New Diagnostic Test for Drug Sensitivity Evaluation in Metastatic Colorectal Cancer

• Status: Not Yet Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 75 (estimated)
• Sponsor: Oncosyne AS · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

DSEE-CRC is a top-tier Norwegian and Swedish public-private partnership for the development of µCAN, a unique patient-centric, therapy-guiding in vitro diagnostic test to improve cancer treatment outcomes for metastatic colorectal cancer patients. µCAN takes a cancer biopsy sample as input and combines proprietary patient-derived tumoroid culturing conditions with state of-the-art machine learning, and computer-vision guided fluorescence high- content drug screening and analysis, to identify the best therapeutical approach for clinical practice. DSEE-CRC will have a positive societal and financial impact and directly contributes to the Good Health and Well-being Sustainable Development Goals by delivering patient-tailored treatments, concurrently increasing cancer survivability rates, improving patients' quality of care, and reducing cancer treatment costs for healthcare providers.

Conditions

• Metastatic Colorectal Cancer (mCRC)

Interventions

Type	Name	Description
DIAGNOSTIC_TEST	µCAN drug screen test	µCAN guided therapy is based on drug screening of patient-derived tumoroids. The patient might be treated with clinically relevant on-label or off-label drugs
OTHER	Standard-of-Care Therapy	trifluridine/tipiracil/bevacizumab combination, 28 day cycles

Timeline

• Start date: 2025-09-01
• Primary completion: 2028-06-01
• Completion: 2029-06-01
• First posted: 2025-09-12
• Last updated: 2025-09-12

Locations

1 site across 1 country: Norway